Osimertinib mesylate 200 mg | 100.00%
TargetMol
Osimertinib (AZD-9291) is an irreversible and mutant selective EGFR inhibitor (IC50s: 12/1 nM for EGFR(L858R) and EGFR(L858R/T790M)).
More Information Supplier PageOsimertinib mesylate
Search Results
S3I-201 200 mg | 99.05%
TargetMol
S3I-201 is a selective Stat3 inhibitor (IC50: 86±33 μM) and low effect towards STAT1/5.
More Information Supplier PageS3I-201
S3I-201 100 mg | 99.05%
TargetMol
S3I-201 is a selective Stat3 inhibitor (IC50: 86±33 μM) and low effect towards STAT1/5.
More Information Supplier PageS3I-201
Infigratinib 200 mg | 98.03%
TargetMol
Infigratinib (BGJ398) is an orally bioavailable pan FGFR inhibitor (IC50: 0.9/1.4/1 nM for FGFR1/2/3), >40-fold selective for FGFR versus FGFR4 and VEGFR2.
More Information Supplier PageInfigratinib
JNJ0966 10 mg | Purity Not Available
TargetMol
JNJ0966 is a highly selective MMP-9 zymogen inhibitor (IC50: 440 nM).
More Information Supplier PageJNJ0966
Gabapentin hydrochloride 100 mg | 99.46%
TargetMol
Gabapentin HCl is a GABA analogue, used to treat seizures and neuropathic pain.
More Information Supplier PageGabapentin hydrochloride
Crizotinib 50 mg | 99.35%
TargetMol
Crizotinib is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.
More Information Supplier PageCrizotinib
Crizotinib 200 mg | 99.35%
TargetMol
Crizotinib is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.
More Information Supplier PageCrizotinib
Crizotinib 10 mg | 99.35%
TargetMol
Crizotinib is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.
More Information Supplier PageCrizotinib
Crizotinib 100 mg | 99.35%
TargetMol
Crizotinib is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.
More Information Supplier PageCrizotinib